Amylyx Pharmaceuticals (AMLX) shares are in focus after the company reported that the final participant has been randomized and dosed in LUCIDITY, its pivotal Phase 3 trial of avexitide for post-bariatric hypoglycemia.
See our latest analysis for Amylyx Pharmaceuticals.
The latest trial milestone arrives as momentum in Amylyx Pharmaceuticals' share price has been building, with a 7 day share price return of 23.98% and a 90 day share price return of 39.02%, set against a very large 1 year total shareholder return of 357.23% but a 3 year total shareholder return decline of 45.34%. Together, these figures point to strong recent enthusiasm after a weaker longer term experience.
If this type of late stage biotech story interests you, it can be useful to compare it with other companies working at the intersection of medicine and algorithms, starting with 37 healthcare AI stocks
With analyst targets sitting above the current US$15.82 share price and no revenue yet from its pipeline, the key question is simple: is Amylyx still underappreciated, or is the recent rally already pricing in future growth?
Most Popular Narrative: 28.7% Undervalued
At a last close of $15.82 versus a narrative fair value of $22.20, Amylyx Pharmaceuticals sits in a zone where expectations and clinical execution really matter.
The company is targeting post bariatric hypoglycemia, a condition with no FDA approved therapies and an estimated 160,000 patients in the U.S., which creates room for a first approved product like avexitide to establish a new revenue line if pricing and access are secured.
Curious what kind of future revenue curve and profit margin shift would need to sit behind that fair value, and how rich a future earnings multiple the narrative is willing to assign if those milestones line up? The full story joins those moving parts into a single valuation path.
Result: Fair Value of $22.20 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, the story still leans heavily on avexitide and LUCIDITY, and any clinical setback or need for extra funding could quickly challenge that 28.7% undervalued case.
Find out about the key risks to this Amylyx Pharmaceuticals narrative.
Another View: Multiples Paint A Tougher Picture
The narrative model and analyst targets point to upside, but the simple P/B check tells a different story. Amylyx trades around 5.7x book value, versus roughly 3x for peers and 2.3x for the wider US Pharmaceuticals group, which hints at less room for error if the pipeline slips.
That kind of premium means you are paying more per dollar of net assets than investors typically accept in this sector. The key question is whether the clinical and commercial setup genuinely justifies that higher bar or if expectations have started to run ahead of fundamentals.
See what the numbers say about this price — find out in our valuation breakdown.
Next Steps
With sentiment clearly mixed between recent gains and longer term volatility, it makes sense to look at the same numbers yourself and decide how comfortable you are with the balance of clinical progress, valuation and funding risk. To round out that view, take a moment to review the 1 key reward and 4 important warning signs.
Looking for more investment ideas?
If Amylyx has your attention, do not stop here. The broader market is full of other opportunities that could fit your goals just as well.
- Target stronger fundamentals by scanning companies highlighted in the solid balance sheet and fundamentals stocks screener (40 results) to see which ones match your risk comfort.
- Hunt for value by checking companies screened as 62 high quality undervalued stocks, so you are not relying on a single story for potential upside.
- Broaden your watchlist with underfollowed names surfaced in the screener containing 25 high quality undiscovered gems that might not yet be on most investors' radars.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com